The severity of the disease is likely to be mild after vaccination against COVID-19, but in some people it may be more severe.
A new medical study has now identified the factors that can cause serious severity or death of COVID 19 in vaccinated people.
The study, from the University of Oxford in the UK, examined data from general practitioners, national immunizations, code 19 testing, hospital admissions and mortality.
It also included data on 6.9 million vaccinators, of whom 5.2 million had been vaccinated.
Of these, 2031 died as a result of COVID-19 while 1929 were hospitalized.
Of those, 71 and 81 hospital admissions were from people who had been using the second dose of the vaccine for more than 14 days.
The researchers looked at various factors, including age, gender and other risk factors for hospitalization and death in vaccinators.
The results showed that people who have a weakened immune system due to chemotherapy, bone marrow or organ transplants or HIV / AIDS have a higher risk.
People who suffer from mental illness, including dementia and Parkinson’s, care home residents and people with chronic illnesses are also at higher risk.
“The UK was the first country in the world to implement a vaccination program and we developed a new tool using the Q Research database,” the researchers said.
He said the tool helped the NHS identify patients at high risk of serious consequences after vaccination.
The researchers said that after using any other dose of the vaccine, very few people were hospitalized or died from the code, making it impossible to clearly identify at-risk groups.
He said a national study of more than 5 million people who had been vaccinated had found that very few people were at risk of hospitalization and death from cod after vaccination.
“Our risk calculator will help identify those who are most at risk after vaccination,” he added.
“Our new QCode tool will help experts across the UK identify high-risk individuals and determine who can be vaccinated with booster doses of vaccines or new therapies such as monoclonal antibodies,” he said. There may be more benefits.
The results of the study were published in the medical journal British Medical Journal.